Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
fda
5
×
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
5
×
boston top stories
clinical trials
new york blog main
new york top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
novartis
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biogen
boston
cancer
deals
deerfield management
eli lilly
europe blog main
europe top stories
gilead sciences
ipo
What
medicines
5
×
fda
approval
bio
covid
drug
ipo
new
roundup
acquisitions
activity
amgen
announced
approvals
biogen
biotechs
blueprint
cancer
candidate
candidates
central
ceo
clamped
class
cns
collabs
currently
daniel
deal
delays
developed
developing
disorder
drugs
economic
emerged
fast
gets
gilead
gilead’s
Language
unset
Current search:
fda
×
medicines
×
" san francisco top stories "
×
@xconomy.com
3 years ago
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines